Results 221 to 230 of about 19,810 (255)

Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy

Current Topics in Medicinal Chemistry, 2013
The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide.
J L, Parus, R, Mikolajczak
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

Seminars in Nuclear Medicine, 2020
Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important modality in the therapeutic armamentarium of advanced, metastatic or inoperable, progressive Neuroendocrine Neoplasms (NENs). This review deliberates on the basic understanding and applied clinical aspects of PRRT in NENs, with special reference to (1) tumor ...
Sandip, Basu, Rahul V, Parghane, , Kamaldeep, Sudipta, Chakrabarty   +3 more
openaire   +2 more sources

Pheochromocytomatosis Treated With Peptide Receptor Radionuclide Therapy

Clinical Nuclear Medicine, 2022
Abstract Pheochromocytomatosis refers to pheochromocytoma tumorlets developed as a result of seeding of tumor cells around the surgical bed due to intraoperative tumor capsule rupture and tumor cell spillage. As pheochromocytomatosis is relatively rare, optimal management is not clear.
Martin S, Auerbach, Masha J, Livhits, Run, Yu   +2 more
openaire   +2 more sources

Peptide-receptor radionuclide therapy for endocrine tumors

Nature Reviews Endocrinology, 2009
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors. Treatment with somatostatin analogs labeled with (111)In, (90)Y or (177)Lu can result in symptomatic improvement, although tumor remission is seldom achieved with (111)In-labeled
Essen, Martijn, Krenning, Eric, Kam, BLR, Jong, Marion, Valkema, R., Kwekkeboom, Dik   +5 more
openaire   +3 more sources

Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2021
TO THE EDITOR: With great interest, we recently read Strosberg et al.’s publication regarding the risk of bowel obstruction in patients with mesenteric or peritoneal disease who receive peptide receptor radionuclide therapy (PRRT) ([1][1]).
Christopher E, Wee, Ayca, Dundar, Rachel A, Eiring, Mohamed, Badawy, Timothy J, Hobday, A Tuba, Kendi, Annie T, Packard, Thorvardur R, Halfdanarson   +7 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors [PDF]

Thoracic Surgery Clinics, 2014
Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane.
Lisa Bodei, Marta Cremonesi, Mark Kidd
exaly   +4 more sources

Renal Dosimetry in Peptide Radionuclide Receptor Therapy

Cancer Biotherapy and Radiopharmaceuticals, 2010
This study evaluates the predictive value of absorbed dose, biological effective dose, and time-dose-fractionation factors for use in patients receiving peptide radionuclide receptor therapy treatments by reanalyzing data in two different patient populations that have been reported in the literature.
Jeffry A, Siegel, Michael G, Stabin, Robert M, Sharkey   +2 more
openaire   +2 more sources

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15 ...
Eric P Krenning, Robin P Peeters
exaly   +4 more sources

Peptide receptor radionuclide therapy of neuroendocrine tumours

Best Practice & Research Clinical Endocrinology & Metabolism, 2016
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177 ...
Brabander, Tessa, Teunissen, Jaap, van Eijck, Casper, Franssen, Gaston, Feelders, R.A., de Herder, W.W., Kwekkeboom, Dik   +6 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

2015
Peptide receptor radionuclide therapy (PRRT) has been a well-accepted and effective therapeutic modality for inoperable or metastatic gastroenteropancreatic, bronchopulmonary and other neuroendocrine tumors for almost 2 decades. In general, PRRT is well tolerated with moderate toxicity in the majority of patients if the necessary precautions ...
Lisa, Bodei, Mark, Kidd, Vikas, Prasad, Irvin M, Modlin   +3 more
openaire   +2 more sources